Bioelectronics Corp (BIEL)

[3331]

BIEL SET UP PERFECTLY FOR A SQUEEZE
Assuming about 15 billion shares of BIEL are in strong hands (hardcore shareholders like me that may never sell), that leaves about 10 billion available to accumulate on the open market. It would take "pocket change" ($2,000,000 @ .0002/share) to "corner" the BIEL market. There are tens of thousands of investors watching BIEL that will jump in as soon as the PPS ticks up. Since the majority of the outstanding shares are in tight hands, the pps will move up like a rocket after ignition, as the supply of available shares will be less than the demand (SQUEEZE!). The PPS would move up while the 10 billion shares were being accumulated, the question is how much. The Reddit crowd would be all over it. With increasing revenues, say a $400k profitable quarter (or hint of), a dime (PPS = .10) wouldn't surprise me.

BIEL VENTURE CAPITAL HEDGE FUND
KEY STAKEHOLDERS: DR. DON BUFORD, DR. SREE KONERU, KEITH NALEPKA, OREL HERSHISER
Each key stakeholder should see RecoveryRx not just as a product, but as an opportunity for professional leadership and financial breakthrough. By distributing RecoveryRx and investing in BIEL shares, they cement their status as visionaries in medical innovation and create a powerful wealth-building opportunity in the highly lucrative medical device market.

Projected Outcomes:
1. Increased distribution of RecoveryRx among medical professionals.
2. Surge in BIEL stock accumulation, leading to exponential valuation growth.
3. Strengthened brand credibility through endorsements from industry leaders.

Executive Summary:
This plan aims to leverage the influence of key industry leaders—Keith Nalepka, Dr. Sree Koneru, Dr. Don Buford, and other medical professionals—to expand the distribution of RecoveryRx and drive investment in BIEL. By capitalizing on their networks and credibility, we can create a powerful movement that positions BIEL for exponential growth.

Strategic Business & Investment Framework for Key Stakeholders:
By leveraging their professional credibility, industry influence, and financial foresight, these individuals can accelerate RecoveryRx distribution, boost BIEL stock valuation, and secure first-mover advantages in a high-growth opportunity.

1. Keith Nalepka – Strategic Leadership & Global Expansion
As President of VLMS Global Healthcare and an ex-BIEL VP of Sales, Keith and VLMS are perfectly positioned to scale RecoveryRx distribution through major healthcare networks.

Immediate Strategy: Structure partnerships between BIEL and VLMS, integrating RecoveryRx into existing medical supply chains.

Investment Thesis: Keith’s direct experience with BIEL grants unique insights into its growth potential, making stock accumulation (by Keith and VLMS) a strategic financial move.

2. Dr. Sree Koneru – Technology & Medical Validation
As a former BIEL VP of Engineering and a high-level executive at Viant Medical, Dr. Koneru is critical for reinforcing technical credibility and expanding RecoveryRx adoption.

Industry Influence: His engineering expertise strengthens the case for RecoveryRx’s scientific legitimacy.

Stock Investment Strategy: His position on BIEL’s board aligns him with long-term value appreciation, making increased share accumulation (by Sree and Viant) a logical financial step.

Institutional Scaling: Collaborate with Viant Medical for large-scale manufacturing and distribution expansion.

3. Dr. Don Buford – Medical Advocacy & Market Expansion
Dr. Buford’s endorsement of RecoveryRx has sparked significant industry interest, as seen in his LinkedIn engagement.

Momentum Tactic: Capitalizing on enthusiastic responses to his post by establishing a formal RecoveryRx distributor network.

Revenue-Driven Investment Strategy: Encouraging physicians who show interest in distribution to also purchase BIEL shares, ensuring dual financial benefit.

MLB Connection Activation: Utilizing his ties within sports medicine to promote RecoveryRx adoption among MLB players and athletic trainers.

4. Orel Hershiser – MLB Endorsement & High-Profile Investment
Orel Hershiser, already a BIEL shareholder, can serve as a sports industry bridge, bringing in MLB investors and sports medicine practitioners.

Investor Activation Plan: MLB players invest in BIEL, seeing long-term financial growth potential in its expanding medical footprint.

Distribution Expansion Strategy: Partnerships with MLB training facilities and medical staff, integrating RecoveryRx into sports recovery protocols.

Media & Branding Enhancement: High-profile endorsements and interviews to accelerate visibility and credibility.

Leveraging Their Collective Influence:
By expanding RecoveryRx distribution and strategically accumulating BIEL shares, Keith (and VLMS), Sree (and Viant), Dr. Buford, and Orel Hershiser position themselves as industry pioneers, driving both medical innovation and wealth-building opportunities in the highly lucrative medical device market.

CORNERING THE MARKET: A STRATEGIC PERSPECTIVE
In the early 1980s, the Hunt brothers famously cornered the silver market, accumulating nearly one-third of the global silver supply. Their massive investment drove prices from $2/ounce to $50/ounce, but when they couldn't meet margin calls, the market collapsed.

Applying the Strategy to BIEL
Unlike silver, BioElectronics Corporation (BIEL) presents a unique opportunity with significantly lower capital requirements and no margin borrowing risk. Assuming 15 billion shares are in strong hands, that leaves approximately 10 billion shares available for accumulation—equivalent to a mere $2 million investment at $0.0002 per share.

Market Dynamics & Potential Price Action
Low Capital Requirement: Compared to the billions needed to manipulate the silver market, cornering BIEL’s available shares would require only pocket change relative to institutional investments.

No Margin Borrowing Risk: The Hunt brothers’ downfall was leverage—with BIEL, strategic accumulation would be fully capital-backed, mitigating collapse risk.

Upward Price Movement: As the 10 billion shares are acquired, price appreciation is inevitable—the key question is how much and how fast.

Catalysts for Growth
Reddit & Retail Investor Interest: If traction builds among the retail investing community (similar to past explosive penny stock movements), momentum could snowball rapidly.

Revenue Growth Validation: A profitable quarter or even a strong revenue hint (e.g., $400K in earnings) could legitimize valuations and send the price per share (PPS) toward $0.10+.

Institutional Engagement: Increased distribution and medical adoption of RecoveryRx could attract larger institutional players, further stabilizing upward movement.

Conclusion
With strategic share accumulation, increasing revenues, and market excitement, BIEL could experience exponential appreciation—presenting a rare opportunity for early movers to corner a low-cap market with limited financial risk. Just sayin'...something for the BIEL VENTURE CAPITAL HEDGE FUND stakeholders to consider.

BIEL IS SIMPLE TO ANALYZE!
Q3 2021 was BIEL's only profitable quarter ($22,381) with $414,700 revenue (including $100k+ in covid relief funds). PROFITABILITY IS VERY CLOSE! Seems like $1.5 million annual revenue (or a $400k quarter) should do it, due to BIEL's extremely low operating costs and business model. Then the corresponding pps should hit .01 - and increase .01 for each additional $2.5 million annual revenue (P/E = 100). The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability. KISS - KEEP IT SIMPLE STUPID! 💋

THIS DISTINGUISHED GROUP COULD EASILY BECOME BIELIONAIRES!
1) LAST WEEK KEITH NALEPKA (EX-BIEL VP SALES) WAS PROMOTED TO PRESIDENT OF VLMS GLOBAL HEALTHCARE.
2) LAST WEEK A PRESITGIOUS GROUP OF DOCTORS/SURGEONS/MEDICAL WORKERS RAVED ABOUT RECOVERYRX.
https://www.linkedin.com/posts/donbufordmd_ever-heard-of-a-tens-unit-or-a-nerve-stimulator-activity-7333861518729465856-vdpb?utm_source=share&utm_medium=member_android&rcm=ACoAAD5fnnMBgcCqTZjoHiMob3xCmYJyZQN5d7A
3) RECENTLY DR. SREE KONERU (EX-BIEL VP ENGINEERING) WAS PROMOTED TO A HIGH-LEVEL MANAGEMENT POSITION AT VIANT MEDICAL AND SOON AFTER WAS APPOINTED TO THE BIEL BOARD OF DIRECTORS.
I think Keith and Sree already own over 100,000,000 shares and that Orel Hershiser also owns a significant amount. If they were to accumulate more, and the rest of the doctors/surgeons mentioned above invested accordingly, they could make BIEL run well over 10,000% (COPPER) in a matter of days/weeks - and much higher if Dr. Buford, Orel Hershiser and Keith Nalepka could tap into their MLB connections (or get some players to invest)!

DISTRIBUTORS AND INVESTORS ARE THE KEY TO SUCCESS!
It was great to see the fabulous replies to Dr. Buford's post. Responses like the following are the key to success for BIEL:
"I'm very excited to look into the possibility of carrying these devices and becoming a distributor."

While all the responses to Dr. Buford's post were excellent, this one deserves particular attention:
"I am also a believer! This thing simply works. I have no conflicts of interest, other than a small margin when my patients purchase one. It is truly impressive how well these work."
While the "small margin" can be remedied by increasing the unit cost, a better solution would be if the sellers and distributors purchased shares while the share price is so ridiculously low. The return on investment for the shares would be exponential (Amazon/Apple/Netflix - like) when the company reports (or hints about) increased revenues.

THE "WELLNESS MARKET" MAY BE THE BIGGEST OF ALL!
There were comments in the Dr. Buford discussion about potential uses for Actipatch/RecoveryRx that have not been FDA cleared. There have been many suggestions and testaments recently for using Actipatch/RecoveryRx "off label" as a "wellness" product (CHA-CHING $$$ without FDA complications - BIEL already has enough FDA clearances!). People have successfully used it for menstrual pain, migraines, diabetic neuropathy, restless leg syndrome (RLS affects 10% of adults worldwide), opioid reduction, bladder issues, etc. There is also huge potential for prostate issues (non-cancerous), as there is evidence that PEMF/PSWT therapy helps with Benign Prostatic Hyperplasia (BPH) symptoms.

❤️32 REASONS TO LOVE BIEL❤️
1. It's a real company with real products.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wringer. They've accomplished FDA clearance (5) already.
3. The company is very close to profitability every quarter. BIEL will likely be profitable soon, if not already (a $400K revenue quarter should do it).
4. There is no toxic debt. The company is not sinking under death spiral financing.
5. Actipatch has thousands of excellent, mostly 5-star customer reviews.
6. The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability.
7. Insider Buying - Significant insider loans (and recent roll-overs) are equivalent.
8. Technical indicators (Golden Cross, Blue Sky Breakout, etc.) turning positive. Every bull run starts with this.
9. Bare bones expenses: about $750k/year for GENERAL AND ADMIN EXPENSES (salaries, utilities, R&D, Advertising, etc) with a burn rate of about $220k/year for Other Gen and Admin Expenses.
10. New utility patent (pending) for chronic pain inflammation (vagus nerve) - HUGE.
11. Accepted for use by the Veterans Administration.
12. BIEL has 5 FDA clearances with more pending.
13. Insurance coverage is expanding - currently covered by the UK National Health Service (and Taiwan?).
14. In business for over 20 years
15. Never reverse split.
16. Rapidly expanding in the veterinary/pet market - RECOVERYRX-VETERINARY could be a GOLDMINE!
17. New contract/partner rumors swirling.
18. Fed forecast to cut interest rates five times this year, which greatly benefits OTC stocks like BIEL.
19. The potential is mind-boggling - especially if Actipatch is identified as a "wellness product" for the applications not currently covered by the FDA clearances (menstrual, depression, migraines, restless leg, etc.).
20. Actipatch will be a Standard of Care product. Actipatch/RecoveryRX have a massive potential market - essentially every human on the planet AND their pets/animals (RecoveryRX Veterinary)!
21. The higher margin RecoveryRX is available by prescription.
22. A new distribution partner for the USA will be announced soon. The last time this happened (2021) BIEL surged 1,600%.
23. BIEL is optimizing the Netflix business model.
24. BIEL COULD HIT COPPER IN THE "BLINK OF AN EYE"!
25. PPS = .001. $800k annual revenue gets the pps out of the trips.
26. PPS = .003. BIEL GOES VIRAL (equivalent to 3,000% 10-year ROI gains in Apple and Amazon)!
27. PPS = .01. Achieved with $400k revenue quarter.
28. PPS = .02. 200,000% increase (equivalent to all time ROI gains in Apple and Amazon) with $5 million profit (P/E = 100).
28. PPS = .03. 300,000% increase (equivalent to all-time ROI gain in Netflix) with $7.5 million profit (P/E = 100).
29. PPS = .04. 400,000% increase (equivalent to 10-year ROI gain in Bitcoin) with $10 million profit (P/E = 100).
30. PPS = .10. Achieved with $25 million profit (P/E = 100).
31. PPS = $1. After loans are paid off and a stock buyback is initiated.
32. See 1 - 31!

BIEL IS THE NEXT BITCOIN (ROI)!
The Bitcoin return on Investment (ROI) is about 40,000% over the past 10 years. BIEL will go viral at PPS = .003, as it would generate massive press (free marketing/advertising) in the news and financial media when they report that the PPS increase is better than the gains in Amazon and Apple (3,000% over the past 10 years). It would solve all of BIEL's problems and create enormous opportunities for the company. The Reddit crowd would be all over it - generating a Bitcoin like frenzy and more free marketing/advertising - which could catapult the PPS to .04 (40,000% ROI on my .0001 shares)!

OTC stocks are heating up, as they always do when a bull market matures. While most trip zero stocks are scams or shells, BIEL is the ONLY trip zero stock that has been in business for over 20 years (without ever doing a reverse split) and has a real product (with five FDA clearances) that gets rave reviews!!!

ACTIPATCH WILL BE A "STANDARD OF CARE" PRODUCT!
While Bitcoin has no underlying value (it's a speculative bubble like Dutch tulips in the 17th century or abstract art), Actipatch has FDA clearances for the treatment of knee, back, wrist, hips, ankles, plantar fasciitis, carpal tunnel and all musculoskeletal pain. Actipatch has incredible value, especially at the low price of $35 - with a much longer battery life (720 hours or several months if extended with the on/off button) than the competition! The Actipatch FDA clearances allow it to be sold over the counter (without a prescription). The higher margin RecoveryRX applications (post operative pain, edema, wound care, etc.) require a doctor order. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet - every month!

BIEL's EASIEST, FASTEST AND MOST LIKELY PATH TO SUCCESS IS:
1) to generate a $400k revenue quarter (or convince investors it's imminent) - which would achieve cash flow positive/profitability and increase the pps to copper.
2) to generate a $1.5 million revenue year (or convince investors it's imminent).
3) if management hints Q1 2025 was profitable, or Q2 will be.
4) if investors value the new distribution and licensing partner for the OTC US market at $300k (gets the pps out of the trips when added it to the $496k of mostly international revenue reported for 2024). If the investor valuation is $1 million, then the pps hits COPPER!

BIEL:
1) gets out of the trips when some hints are dropped - triggering the Golden Cross (.0004)/Blue Sky Breakout (.0005) technical indicators.
2) PPS = .003 = 3,000% increase (better than Apple and Amazon over the past 10 years), when the new US distributor is announced - and then GOES VIRAL!
3) PPS = .02 = 200,000% increase with $5 million profit/P/E = 100 (equivalent to Apple and Amazon from their low point).
4) PPS = .04 = 400,000% increase with $10 million profit/P/E = 100 (equivalent to Bitcoin over the past 10 years).
5) PPS = .10 with $25 million profit/P/E = 100.

MISCELLANEOUS
1) Re: "read the financials" posted ad nauseum - Hindsight is 20/20 vision - the past financials are what provided this opportunity to buy BIEL at this low price before it becomes the next Amazon, Apple, Netflix, Bitcoin...Investing is about the future, not the past!
"I got vision and the rest of the world wears bifocals" - Butch Cassidy.
2) Re: "shareholders will sell at the first opportunity" posted ad nauseum - To the contrary, shares are currently in "strong hands" and thousands of investors are watching BIEL and will jump in at the first uptick (Golden Cross/Blue Sky Breakout) as evidenced by BIEL routinely being at the top of the Breakout, Most Read, Most Viewed and Most Active boards. The demand for shares will outweigh the supply well into COPPER!
3) The bashers appear to be lonely people starved for conversation and attention that they can only find on this board - SO SAD!
4) The disgusting dislikes (toilet emoji, etc.) on posts honoring our military says all you need to know about the bashers character.
5) Bashers are becoming disgusted and embarrassed with the ignorance being repeatedly displayed by their fellow bashers (bashers bashing bashers - funny!)
6) FREAK OFF PUFF DADDER!

BIEL GOES VIRAL AT PPS = .003!
Market cap = $75 million at pps = .003, which would generate massive press (free marketing/advertising) in the news and financial media when they report that the pps increase is better than the gains in Amazon and Apple (3,000% over the past 10 years). It would solve all of BIEL's problems and create numerous opportunities for the company. The Reddit crowd would be all over it (generating massive free online marketing/advertising). If the company then declares profits would be used for a share buyback program (after paying off the loans), the pps would soar ($1+) and the rise would be sustained.

BIEL COULD HIT COPPER IN THE "BLINK OF AN EYE"!
The first catalyst will likely be the announcement of a partner for the USA, which could come any day. The key statement from the annual report is "The Company has focused attention on seeking a distribution and licensing partner for the OTC US market". If investors value this partnership at $300k (and add it to the $496k of mostly international revenue reported for 2024), the pps gets out of the trips. If the investor valuation is $1 million, then the pps hits COPPER! The last time this happened (KT deal in 2021), BIEL soared 1,600%.

RECOVERYRX-VETERINARY COULD/SHOULD BE A GOLDMINE!
The Assisi Loop sells over 300/month just on Amazon @ $329, with 1/20 the battery life. Assisi Loop customers are paying the equivalent of over $6,000 when you factor in the additional cost and lower battery life, but Assisi customers seem happy to pay it based on the numerous 5-star reviews. RecoveryRx/Veterinary should be sold as a two/pack - one applied on the vagus nerve and the other attached on the area of pain.

INSIDER BUYING - HUGE!
The best indicator for predicting a company's future is insider buying. The extensive insider loans (and recent roll-overs) identified in BIEL's annual reports basically have the same effect as insider buying. Insider loans are actually better, as they allow the company to avoid toxic lenders. The insider investment/market cap ratio for BIEL is higher than any other company on the market.

BIEL OPTIMIZING THE NETFLIX BUSINESS MODEL!
Netflix has increased over 325,000%, from .35 (on 10/9/02) to about $1,150 today!
1) Product price is about the same and Actipatch lasts as long as a monthly Netflix subscription (much longer when the on/off switch is utilized).
2) Actipatch/RecoveryRX has much larger market potential. While both are available to virtually every human on the planet, RecoveryRX Veterinary is also available to their pets! Also, the high margin RecoveryRX is available by prescription, and the "wellness market" is available for the aches and pains not covered by FDA clearances (menstrual, migraine, restless leg, depression, etc. - simply attach it over the vagus nerve!).
3) BIEL's product profit margins are much higher as their operating costs are virtually nothing compared to Netflix (no movie studios and actors required to constantly put out new content).

In advance of the usual illiterate responses such as "you need to enroll in a couple of basic business courses at your local community college" and "if you don't know, I'm not going to explain it", I'll repeat my offer to meet with the basher/whiner/ambulance chasers to compare college degrees and professional work experience. I suspect the Mayflower mover/insurance office staffer with the AutoCAD (2-day training) certificate would be the most educated - although he appears to have a problem understanding English (ESL?) and lately is on a DELIRIOUS rampage calling his basher followers stupid idiots. It would be so interesting to meet the people who devote their lives to bashing a small company trying to achieve the American Dream. Who does that?

SOON
BIEL's easiest, fastest and most likely path to success is to generate a $400k revenue quarter and/or a $1.5 million revenue year (or if management hints Q1 2025 was profitable, or Q2 will be). A $400k revenue quarter would achieve cash flow positive/profitability and increase the pps to copper, which would solve most of BIEL's problems and open up a world of opportunities for the company.

The analyses provided below demonstrate the connection between revenues, profitability and the pps using standard analysis methods. Even if only 10% of the "catalysts" identified below materialize, the pps will still hit copper. This would generate a huge amount of free publicity in the financial and news media (an example of capitalism at it's finest - achieving the American Dream!), which would then lead to an exponential increase in product sales. With BIEL's low operating costs and business model, BIEL could pay off their loans quickly and then use subsequent profits to implement an aggressive stock buyback program, which could rocket the pps to $1+!

PROSPECTUS
BIEL's low-cost OEM business model has put the company in position to be profitable soon such that if investors project for 2025:
1) Annual revenue of $800k - this will be a significant increase from the previous three years and get the pps out of the trips;
2) $1.5 million annual revenue (or a $400k quarter) - this will likely achieve cash flow positive/profitability and get the pps to copper.
3) BIEL's prospects for achieving a 1,000% to 10,000% increase in pps are better than any other company on the market right now!
4) The path to profitability will be accelerated by the tax-loss carryforward of about $40 million (no tax on first $40 million profit).
5) BIEL GOES VIRAL AT PPS = .003!
Market cap = $75 million at pps = .003, which would generate massive press (free marketing/advertising) in the news and financial media when they report that the pps increase is better than the gains in Amazon and Apple (3,000% over the past 10 years). It would solve all of BIEL's problems and create numerous opportunities for the company. The Reddit crowd would be all over it (generating massive free online marketing/advertising). If the company then declares profits would be used for a share buyback program (after paying off the loans), the pps would soar ($1+) and the rise would be sustained.
6) PPS = .02 = 200,000% increase (equivalent to Apple, Amazon and Netflix from their low point). Requires $5 million profit (P/E = 100). Profits will be accelerated by the tax loss carryforward (no tax on first $40 million profit)!
7) PPS = .10: Requires $25 million profit (P/E = 100). Profits will be accelerated by the tax loss carryforward (no tax on first $40 million profit).

Hope this Tik-Tok sensation is part of the BIEL Whelan family!
https://goss.ie/showbiz/spotlight-on-irish-ti...lan-303910

POTENTIAL
The potential is mind-boggling - especially if Actipatch is identified as a "wellness product" for the applications not currently covered by the FDA clearances.

From the 2024 Annual Report:
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.

The chronic pain market is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers. The Company’s medical devices modulate the body’s nerve activity to dampen the pain perception, which reduces drug use. RecoveryRx will be an ideal choice in reducing postoperative pain and exposure to long-term effects of opioid/NSAID therapy.

The technology has the potential to become the standard of care throughout the healthcare continuum across the OTC and healthcare markets. BioElectronics’ technology offers significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.

In February 2020, BioElectronics obtained a new 510(k) clearance from the U.S. FDA, granting over-the-counter marketing clearance for the drug-free ActiPatch medical device, to cover all musculoskeletal pain complaints. This paves the way for new products to treat all medical claims for musculoskeletal pain, including in the back, knee, hips, wrists, elbow, and ankle.

DR. OZ
The Dr. Oz effect will be interesting, considering his recent appointment as Administrator of the Centers for Medicare and Medicaid Services. When Actipatch was featured on the Dr. Oz show, it achieved record sales and sold out the inventory.

BIEL GONNA RUN LIKE 2021!
Everything is falling into place just like 2021. A new distribution partner for the USA will be announced soon (replacing the KT deal from 2021). OTC bull market runs are fueled by the Fed cutting interest rates, and the Fed is now forecast to cut five times this year. Falling interest rates indicate a more accommodative money policy which makes investors more interested in the higher risk/higher reward stocks found on the OTC. The last time this happened, BIEL ran more than 1,600% to .0088. The previous BIEL runs coincided with similar OTC bull markets in 2017, 2014 and 2009.

The technical indicators come first - the Golden Cross and the Blue Sky Breakout. Then the fundamentals kick in (Taiwan, VA, Veterinary, New Zealand...). BIEL is a Reddit investors dream. Once they become aware of BIEL (via the financial press), the pps will rocket, product sales will soar, and we'll be celebrating like 2021! https://microcapdaily.com/exciting-week-for-bioelectronics-corp-otcpink-biel/124825/

Expect a 5,000% ROI (pps = .005 from .0001) when BIEL reports a profit - or if management hints Q1 (2025) was profitable. This would put BIEL amongst the all-time greatest stocks.
Gemini says "a 5,000% ROI is fantastic but very rare and typically associated with high-risk investments such as penny stocks or early-stage startups".
Copilot says: "achieving a 5,000% return on investment (ROI) is rare and typically involves high-risk stocks, often in emerging industries or during market booms. Some penny stocks, for example, have been highlighted for their potential to deliver such returns".

BIEL IS THE NEXT AMAZON/APPLE (in terms of ROI)!
When BIEL hits .003, the return on investment for a .0001 buy (for those of us fortunate enough to get them recently) will be about the same as the 10-year ROI (3,000%) for Amazon and Apple (stocks I sold too soon). Microsoft 10-year ROI is ONLY 900%. BIEL can hit .003 in IN THE BLINK OF AN EYE, as $1.5 annual revenue (or a $400k quarter) should do it (due to BIEL's extremely low operating costs and business model). There are many indications that this will be accomplished soon, if it hasn't been already! We know that Taiwan, the VA, South Africa and Bulgaria are in progress, as is RecoveryRx-Veterinary in Europe (with the USA pending). Canada is expanding, New Zealand sales started March 1 and hopefully Australia will soon follow.

BIEL is a Venture Capitalist Dream! The opportunity to get in on the "next big thing", but with a company that has been in business for over 20 years (rather than a start-up). BIEL is probably the closest that any of us will get to having a venture capital kind of opportunity.
1) BIEL products have Standard of Care pain management potential for every adult and pet on the planet.
2) BIEL has 5 FDA clearances (with more pending) and the products work extremely well (some say like a miracle).
3) Upside ROI is huge (>10,000%) with minimal downside risk!
4) BIEL should be able to use their China manufacturer to ship directly to their international distributors and Viant for their USA sales to avoid tariffs.

BIEL HITS COPPER WHEN THE FOLLOWING OCCURS!
pps > .001 after management drops some positive hints. The Golden Cross (already achieved) and Blue Sky Breakout will get the technicians/chartists/Reddit crowd attention and the pps out of the trips;
pps > .01 after management drops some positive hints that convinces investors that break even/cash flow positive (annual rev = $1.5 mil) will be achieved, combined with the momentum from a 2021 like OTC run (fueled by the Reddit crowd);
pps > .04 after pr indicates the annual revs from Taiwan (in progress) can be valued at $10 mil+;
pps > .08 after pr indicates the annual revs from the VA (in progress) can be valued at $10 mil+;
pps > .12 after pr indicates the annual revs from RecoveryRx Veterinary (pending) can be valued at $10 mil+;
pps > .16 after pr indicates the annual revs from new contracts (distributors, partners, New Zealand, etc.) can be valued at $10 mil+;
Above pps values are based on P/E = 100
For P/E = 200, pps = .32
For P/E = 300, pps = .48
pps > $1 after loans are paid off and a stock buyback is initiated.

CATALYSTS (Details):
1) USA distribution partner announcement.
2) Taiwan - there are over 80 public hospitals and over 400 private hospitals in Taiwan. They have national health insurance and are rated the world's number one health system.
Assume 100 Taiwan hospitals order 100 Actipatch/RecoveryRx per month @$100 each for BIEL:
$100 x 100 hospitals x 100 x 12 mo = $12,000,000 rev/year.
Using profit = $10 mil and P/E = 100: PPS = .04.
Note: RecoveryRx Veterinary also appears to be in play in Taiwan.
3) 1000 Veterinarian Clinics (USA):
Conservatively assume each office orders 10/mo. @ $100 each for BIEL (Vet sells for $200, a bargain compared to Assisi):
1000 x 100 x 10 x 12 = $12,000,000 rev/year.
Note: RecoveryRx Veterinary also appears to be in play internationally.
4) Veterans Administration: There are over 1,000 VA facilities in the U.S. Conservatively assuming 100 VA hospitals order 100 RecoveryRx per month ($100 each for BIEL):
100 x 100 x 100 x 12 = $12,000,000 rev/year.

Sub-total for VA + VET = Using $20 mil (profit) and P/E = 100: PPS = .08!
TOTAL (Taiwan + VA + Veterinary + applying the tax loss carryforward):
pps = .12 (P/E = 100)
pps = .24 (P/E = 200)
pps = .36 (P/E = 300)
Additional revenue could be generated from new FDA clearances, vagus nerve patent, NPA, UK/Australia contract rumor, RecoveryRx Veterinary international sales, New Zealand, etc. Initiating a stock buyback program after all of the loans are paid off would propel the pps much higher (pps = $1).

BIEL FACT CHECK:
1) The basher/ambulance chasers repeatedly complain about the nearly 25 billion shares outstanding, but they can't provide a single reason why. It's irrelevant as it is accounted for in the VALUATION (pps) - 25 billion shares @.0002 = $5 million is the same valuation as 1 million shares at $5/share. NVIDIA has the same number of shares outstanding as BIEL, Apple and Amazon will soon have billions more (after the next split), and nobody is concerned! The stock market is all about valuation (outstanding shares x pps) - you buy if you think a stock is under-valued and sell if you think it is over-valued. Only amateurs/newbies/bashers do not understand this simple concept. Right now, investors feel BIEL is fairly valued between $2.5 - 5 million, but if news develops where investors feel $1 billion is fair value, you will see the BIEL pps rise accordingly (pps = .04). Some have tried to dispute this by changing the subject to dilution. BIEL has not diluted significantly in many years, and there is no indication it will in the future. The low pps is actually an advantage at this point, as it makes BIEL affordable to any investor (big and small). If you have $1,400 to invest, would you rather own 7 million shares of BIEL or 1 share of O'Reilly Auto Parts? The Reddit crowd would definitely choose BIEL.

2) BIEL's valuation is currently $5 million for revs of $715k (2023), which is undervalued compared to stocks (like SERV and QUBT for example) with billion-dollar valuations but only half of BIEL's revenue. When people become aware of the benefits of PSWT/PEMF and the huge multi-billion-dollar drug free pain management market - that desperately needs FDA cleared Actipatch/RecoveryRx/RecoveryRx Veterinary- BIEL will SOAR!

3) BIEL has been in business for over 20-years and has NEVER done a reverse split, which is VERY IMPRESSIVE!

4) Supply/Demand - the majority of the outstanding shares are in tight hands, so the pps will move up like a rocket after ignition, as the supply of available shares will be less than the demand (SQUEEZE!). Shareholders can help fuel the blast off by locking up their shares with "good until cancelled sell orders" (@$1) so their shares cannot be borrowed by the short sellers, thereby further reducing the supply.

BUYOUT
Right now, I doubt anything under $50 million would be considered (accounting for loans, etc.). That's out of my range, but in the future - after the pps increases, loans are paid off and a share buyback is implemented - I could see a point where a group of shareholders could get together and leverage their shareholdings to make an offer. Years ago, Simpsonly and some other shareholders made an offer to Andy but were turned down. Not sure if Orel Hershiser was part of that group, but he is rumored to be a shareholder and a big fan of the products (would be a great influencer for BIEL).

LICENCE/PARTNER/MERGER?
The Signal Relief Patch (in business for a little over a year) costs about twice as much as the Actipatch, but is much less effective at reducing pain and will probably never gain FDA approval. However, they do have lots of money for marketing and advertising - their ads are on national TV every day, along with on-line media. They might be a good partner for Actipatch - we could use their advertising/marketing budget, and they could use Actipatch (integrated with their patch) to make their device more effective at reducing pain. It could work the way the KT licence was supposed to. Signal Patch is private now, so a merger with BIEL would give them quick access (compared to an IPO) to the stock market, where their venture capitalists would get a better return on their investment (than stay private).

REVIEWS (5 STAR)
BIEL technology works and sells WHEN people become aware of it and where to buy, as demonstrated by the Recovery Wave, which is Amazon's "Overall Pick" and a hot seller (over 700 per month) with rave reviews (STANDARD OF CARE like), such as:

Green Light ON...Pain is Gone!
Reviewed in the United States on May 5, 2025
I've been using this for a few years now and works great on my lower back and knee pain. I put one on my lower back before golf each week and zero pain. Highly recommend and don't leave home without it.

5.0 out of 5 stars Verified Purchase
Amazingly effective for such a little, simple device
Reviewed in the United States on October 29, 2024
I knew about these loops because a vet used an Assissi loop, this one’s big brother, to heal my agility dog’s back end when she sprained it badly. So I thought I’d try this smaller, cheaper and more portable unit to help with healing and pain from a fractured sacrum that had been hurting for 9 months. I had to leave this device on for several hours at a time. After about two hours on I noticed pain diminishing the first time I wore it. Now after about a month of sporatic use (ie, only when I had pain or did activities I knew that brought on pain) I am living mostly pain free! I also have been doing my PT exercises and they help too, but the pain wasn’t diminishing much with exercises alone. Another advantage of this unit is that it doesn’t shoot a current through your body like a tens unit, which I find very disagreeable. I will keep a KT Wave Recovery loop on hand for times when I need it.

RecoveryRX is also getting great reviews (May 2025):
Steven Ray Garcia Owner/Operator-Sandlot Medical: "This is a great product. I work with a couple top Plastic Surgeons in Scottsdale, and Recovery RX is part of their breast augmentation recovery protocol."

IS BIEL THE NEXT MSFT?
Those that bought one share of Microsoft at the IPO price of $21 saw their investment increase to $210,000 recently (10,000 X). Someone buying 1 million shares of BIEL @.0002 would see their $200 investment grow to $2,000,000 (pps = $2) with equivalent growth. Is this possible? Absolutely, after BIEL becomes profitable, pays off their loans and then implements an aggressive stock buyback program!

SUPPLEMENT 1 (courtesy of beacham)
I think what is happening is BIEL has ‘a deal’ w/ one of the suppliers/distributors to CMMS and/or the VA. I also think we have an emerging contract relationship w/ Viant and that is the reason Dr. Sree Koneru is on our BOD.

These presumptions (opinions) solve a lot in terms of logistics and financials. For manufacturing, it removes the uncertainty of a China-based supplier of product. Taiwan is a flashpoint and relations w/ China are strained. Viant has international reach that can supply product to any of our distributors worldwide w/o all the drama and tension, not to mention shipping time, of having a manufacturer thousands of miles away in a potentially hostile situation. How this ties into the paucity of Raw Materials expenditures over the last 4 yrs is a good question. We keep CICD for the Asian distribution but should circumstances change, we have Viant. They also have a Design & Development division. It’s a smart move.

Working w/ a ‘local’ supplier to CMMS and/or the VA takes the buyout scenario off the table for now. It does, however, give BIEL some certainty in terms of revenue and, if/when announced, would do wonders for the share price.

The logistics of this are complicated, complex, time sensitive and politically charged, involving not only the nuts and bolts but official approvals as well. I think the Atlanta sites are a pilot project / launch-point to work out the myriad details. Working through a supplier who has already done the paperwork to work w/in the CMMS and/or VA bureaucracies is a huge bonus. They would ‘simply’ add our products to their catalog. Doing the legwork to make that happen would be their responsibility and thus freeing us to focus on supplying product to them for their distribution to the numerous CMMS and/or VA locations.

It would also explain having an NDA and the near total silence that ensues. Nobody needs or wants an army of bashturds crawling up your backside agitating for the impossible. The scope and magnitude of this project is enormous, beyond words. CEO Kelly Whelan has not been given enough credit, in my opinion. And all of this work must be done under the radar, by legal necessity, as per an NDA. Lots of moving parts and endless details. When CEO Kelly says they are working, I believe her.

SUPPLEMENT 2 (courtesy of beacham)
Let’s assume that BIEL will get the CMS and the VA contract. If/when that announcement(s) takes place, whether simultaneously or separately, the explosion in the share price will make Mt. Vesuvius look like a backyard firecracker on the 4th of July. Now, I ask you, would that make you stay ‘mum’ on any of the details ??? Yea, me too.

The share price would not hit copper in a week. It would happen before lunch. By the time you entered an order at a specific price, the price will have jumped to the next level. Either buy at ‘market’ or forget it. The price would explode. Dare to dream and imagine.

3331 has been restricted to one post per day (for months) which is often deleted.